Structure Therapeutics Reports $106.2 Million Net Loss in Q2 2026

Structure Therapeutics Inc. reported significant financial results for the second quarter of 2026, revealing a net loss of $106.2 million, compared to a loss of $61.7 million in the same period of 2025. For the six months ending June 30, 2026, the company recorded a net loss of $182.1 million, up from $108.5 million in the prior year. The increase in losses is attributed primarily to a substantial rise in operating expenses, which totaled $118.6 million for the quarter and $208.0 million for the half-year, reflecting an 83% increase in research and development costs driven by clinical trial expenses and personnel costs.

The company’s cash, cash equivalents, and short-term investments stood at $1.34 billion as of June 30, 2026, a decrease from $1.58 billion at the end of 2025. This decline is largely due to cash used in operating activities, which amounted to $104.9 million in the first half of 2026. Structure Therapeutics has not yet generated revenue from product sales, as it remains focused on advancing its clinical pipeline, which includes its lead candidate, aleniglipron, currently in Phase 3 trials for obesity treatment.

In terms of strategic developments, Structure Therapeutics has made notable progress with its product candidates. The company initiated the Phase 3 ACCOMPLISH program in August 2026, which includes two trials evaluating aleniglipron in adults with obesity and type 2 diabetes. Additionally, the company has expanded its pipeline with two oral small molecule amylin receptor agonists, ACCG-2671 and ACCG-3535, with ongoing clinical trials expected to yield results in the coming quarters.

Operationally, the company has increased its workforce to support its growth, with general and administrative expenses rising by 18% to $18.6 million in the second quarter of 2026. Structure Therapeutics is also actively pursuing collaborations and licensing agreements to enhance its product development capabilities. The company received a $100 million upfront payment from Genentech in January 2026 as part of a licensing agreement, which is expected to bolster its financial position.

Looking ahead, Structure Therapeutics anticipates continued investment in research and development, with plans to fund its operations through existing cash reserves and potential future capital raises. The company projects that its current financial resources will be sufficient to support its operations through at least the end of 2028, although it acknowledges the need for additional funding to sustain its growth and development initiatives.